Methoxamine exhibits negative inotropic effects and acts as a competitive antagonist at the adrenergic beta receptor in dog heart-lung preparations.
Answers are grounded in this paper and cite their sources.
These effects in canine preparations should not change practice; leaves open translation to intact models or catecholamine interactions in humans.
The cardiac action of large doses of methoxamine and its antagonistic action to epinephrine were studied, using a dog heart-lung preparation. In doses of 4 mg. and above, methoxamine showed a marked negative inotropic action, while it produced only a slight decrease in the heart rate. Pretreatment of animals with 0.1 mg./Kg. of reserpine did not modify the inotropic action, but the decrease in the heart rate disappeared. Simultaneous with these changes, a decrease in the coronary flow and a rise of the pulmonary arterial pressure were observed. Methoxamine in doses of 1 mg. and more abolished both the positive inotropic and the positive chronotropic actions of epinephrine. The negative inotropic action of methoxamine was ascribed to a nonspecific, as yet undetermined mechanism, and the antagonistic action was ascribed to the competitive antagonism at the receptor site (thus methoxamine may be looked upon as a blocking agent of adrenergic β receptor). The weak negative chronotropic action was taken to be an expression of the blockade of the humoral effects of the intrinsic sympathomimetic amines.
No takes yet. Share an insight, caveat, or question.
Imai et al. (1961) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: